Transgene Management
Management criteria checks 2/4
Transgene's CEO is Alessandro Riva, appointed in Jun 2023, has a tenure of 3.08 years. directly owns 0.034% of the company’s shares, worth €67.29K. The average tenure of the management team and the board of directors is 2 years and 3.3 years respectively.
Key information
Alessandro Riva
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Narrative Update • Jun 23
TNG: Early Cancer Vaccine Data Will Drive Future Repricing
Analysts have kept their fair value estimate for Transgene steady at €1.10 per share, with a slightly higher implied future P/E multiple that reflects updated assumptions on discount rates and long term profitability. What’s in the News for Transgene Transgene initiated a randomized Phase 1 trial of TG4070 in combination with nivolumab as adjuvant treatment for patients with resected non small cell lung cancer.Narrative Update • Jun 05
TNG: Phase II Head And Neck Data Will Drive Future Repricing
Analysts have adjusted their fair value estimate for Transgene stock to €1.10 per share. This change reflects updated assumptions on discount rates, profit margins and a significantly higher future P/E multiple in their models.Narrative Update • Apr 23
TNG: Phase II Head And Neck Progress Will Drive Future Repricing
Analysts have kept their price target for Transgene broadly steady at €1.10, citing updated assumptions around discount rates, profit margins and future P/E that refine rather than overhaul their valuation view. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed €1.10 target as a signal that core valuation inputs such as discount rates and profit assumptions still support the current framework rather than requiring a reset.Narrative Update • Apr 09
TNG: Phase I Head And Neck Data Will Support Future Repricing
Analysts have adjusted their price target on Transgene to €1.10, based on updated assumptions that include a very large change in revenue growth expectations, a lower discount rate, and a revised future P/E of about 13x. Analyst Commentary Bullish Takeaways Bullish analysts view the revised €1.10 price target and the use of a P/E of about 13x as a sign that current assumptions aim to better align valuation with the risk profile investors are willing to accept.Narrative Update • Mar 25
TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have kept their price target on Transgene broadly in line with prior views, with only marginal tweaks to inputs like the discount rate and long term P/E assumptions, indicating a steady valuation framework in euro terms rather than a meaningful reset. What's in the News Transgene released a preprint on medRxiv covering clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic cancer vaccine for operable head and neck cancers (medRxiv).Narrative Update • Mar 11
TNG: Phase I Head And Neck Vaccine Data Will Support Future Repricing
Analysts have maintained their price target for Transgene at €1.10, reflecting largely stable assumptions on the discount rate, revenue trends, margins, and future P/E expectations. What's in the News Transgene released a preprint on medRxiv with a comprehensive analysis of clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine.Narrative Update • Feb 24
TNG: Phase I Head And Neck Data Will Drive Future Repricing
Analysts have reduced their price target for Transgene to €1.10 from €2.00, reflecting updated assumptions that include a higher discount rate, lower revenue growth expectations, improved profit margin and a lower future P/E multiple. What's in the News Transgene released a preprint on medRxiv detailing clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine for operable head and neck cancers (medRxiv preprint).
Narrative Update • Feb 10
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target on Transgene slightly, reflecting updated assumptions for a discount rate, revenue growth of 33.57% and a forward P/E of 27.97x, while keeping fair value at €1.10. This suggests a more finely tuned view of the company’s risk and earnings profile rather than a major shift in outlook.Narrative Update • Jan 26
TNG: Individualized Cancer Vaccine Platform Will Drive Future Upside Potential
Analysts have adjusted their price target for Transgene, citing updated assumptions on discount rate, revenue growth, profit margin and a lower future P/E multiple as key drivers of the change in valuation. The new target is presented in line with a fair value estimate of €1.10 per share.Narrative Update • Jan 12
TNG: Clinical Progress And Capital Raise Will Support Future Upside
Analysts have adjusted their price target for Transgene, citing updated assumptions that keep fair value at €1.10 while reflecting different views on revenue growth, profit margins, and a higher future P/E multiple. What's in the News Preprint publication on medRxiv shares clinical and translational data from the Phase I part of Transgene's randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine, with the manuscript also submitted to a peer reviewed journal for evaluation (Product related announcement).Narrative Update • Dec 14
TNG: Pipeline Progress And Stronger Balance Sheet Will Drive Future Upside
Analysts have moderately reduced their price target on Transgene, cutting fair value by about 20 percent to approximately 1.10 euros. They have incorporated slower expected revenue growth, a higher discount rate, and a more balanced, though significantly improved, long term profit margin outlook into their models.Analysis Article • May 27
Is Transgene (EPA:TNG) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Narrative • Apr 07
TG4050 Trial And Pipeline Developments Will Transform Cancer Vaccines
Progress in TG4050 trials could establish Transgene as a leader in cancer vaccines, boosting reputation and revenue opportunities.Analysis Article • Jun 15
Is Transgene (EPA:TNG) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Mar 21
Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term
One thing we could say about the analysts on Transgene SA ( EPA:TNG ) - they aren't optimistic, having just made a...Analysis Article • Mar 19
Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Transgene SA ( EPA:TNG ) released its full-year result to the market. The early...Analysis Article • Mar 18
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Nov 24
Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Apr 16
Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -€38m |
| Sep 30 2025 | n/a | n/a | -€37m |
| Jun 30 2025 | n/a | n/a | -€37m |
| Mar 31 2025 | n/a | n/a | -€35m |
| Dec 31 2024 | €840k | €600k | -€34m |
| Sep 30 2024 | n/a | n/a | -€28m |
| Jun 30 2024 | n/a | n/a | -€23m |
| Mar 31 2024 | n/a | n/a | -€23m |
| Dec 31 2023 | €510k | €350k | -€22m |
| Sep 30 2023 | n/a | n/a | -€28m |
| Jun 30 2023 | n/a | n/a | -€33m |
| Mar 31 2023 | n/a | n/a | -€33m |
| Dec 31 2022 | €304k | n/a | -€33m |
Compensation vs Market: Insufficient data to establish whether Alessandro's total compensation is reasonable compared to companies of similar size in the French market.
Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.
CEO
Alessandro Riva (66 yo)
3.1yrs
Tenure
€840,000
Compensation
Dr. Alessandro Riva, M.D., serves as an Independent Director at Bicycle Therapeutics plc since March 25, 2025. He serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 3.1yrs | €840.00k | 0.034% € 67.3k | |
| VP & Chief Financial Officer | 2.3yrs | no data | no data | |
| Chief Technical Officer | 1.3yrs | no data | no data | |
| Chief Scientific Officer | 1.8yrs | no data | no data | |
| VP, General Counsel & Corporate Secretary | 10.3yrs | no data | no data | |
| Chief Human Resources Officer | 2.3yrs | no data | no data | |
| VP & Chief Business Officer | 2.5yrs | no data | no data | |
| VP of Medical Affairs & Chief Medical Officer | 1.8yrs | no data | no data | |
| Head of Translational Medicine | no data | no data | no data | |
| Interim Chief Quality Officer | less than a year | no data | no data | |
| Interim Deputy CEO of Responsible Pharmacist | less than a year | no data | no data | |
| VP & Director of Human Resources | no data | no data | no data |
2.0yrs
Average Tenure
50yo
Average Age
Experienced Management: TNG's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 4.2yrs | €840.00k | 0.034% € 67.3k | |
| Director | 26.5yrs | €26.00k | 0.038% € 74.4k | |
| Non-Independent Director | 13.1yrs | no data | no data | |
| Independent Director | 4.2yrs | €24.00k | no data | |
| Member of Scientific Advisory Board | 3.3yrs | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Scientific Advisor | less than a year | no data | no data | |
| Independent Director | 3.2yrs | €45.00k | no data | |
| Director | 5.5yrs | no data | no data | |
| Scientific Advisor | less than a year | no data | no data | |
| Director | 2.2yrs | no data | 0.00016% € 316.8 |
3.3yrs
Average Tenure
64yo
Average Age
Experienced Board: TNG's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/23 10:34 |
| End of Day Share Price | 2026/07/23 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Transgene SA is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arsene Guekam | CIC Market Solutions (ESN) |
| Michael Thomas Cooper | Edison Investment Research |
| Martial Descoutures | ODDO BHF Corporate & Markets |